Viking Therapeutics released results from a phase 2 clinical trial for its experimental weight loss drug. People who received weekly injections of the drug lost up to 14.7% of their body weight over 13 weeks, researchers found.
Viking Therapeutics released results from a phase 2 clinical trial for its experimental weight loss drug. People who received weekly injections of the drug lost up to 14.7% of their body weight over 13 weeks, researchers found.
Our website services, content, and products are for informational purposes only. Healthline does not provide medical advice, diagnosis, or treatment and should not be used as a substitute for medical advice from a healthcare professional. Healthline encourages you to make any treatment decisions with your healthcare professional. Healthline is owned by RVO Health.
